Inactive Instrument

Press Releases Recipharm AB (publ)

Equities

RECI B

SE0005757267

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Åsa Bergström New COO at Nanologica AB (publ)	Apr. 11	AQ
Blue Wolf Capital to Acquire OSD CDMO Sites from Recipharm	Apr. 03	AQ
Recipharm attains major sustainability milestones	Mar. 27	AQ
Recipharm, Medspray, and Resyca enter into exclusive license agreement to develop nasally-delivered drug products using proprietary soft mist technology	Jan. 24	AQ
ReciBioPharm partners with Acuitas Therapeutics to provide rapid technology transfers and CGMP manufacture of Acuitas LNP formulations	Dec. 12	AQ
Recipharm announces collaboration with Oz-UK to accelerate the development of low global warming potential pMDIs utilising HFA-152a propellant	Dec. 06	AQ
Marc Funk to transition to Recipharm's Board of Directors, Greg Behar appointed new CEO, Inhaled Business to standalone in 2024	Nov. 22	AQ
Fitch Affirm Recipharm at 'B'; Outlook Stable.	23-09-15	AQ
Recipharm - Earthquake in Morocco	23-09-11	AQ
Recipharm partners with Ahead Therapeutics to develop rare autoimmune disease therapy	23-09-06	AQ
Recipharm and Honeywell to speed development of inhalers with a near-zero global warming potential propellant	23-08-18	AQ
Recipharm's new analytical lab brings impressive testing capabilities to global markets	23-07-12	AQ
Arranta Bio, a Recipharm company, signs contract with MIT to develop rapid manufacturing of mRNA therapeutics	23-05-01	AQ
Recipharm bolsters senior leadership team with appointment of Joaquim Mascaro as Chief Financial Officer	23-04-05	AQ
Recipharm's Arranta Bio expands RNA process development capacity by 50 per cent to meet increased customer demand	23-03-10	AQ
PAVM, CHAI & PATH Joint Site Visits With African Vaccine Manufacturers - Fact Finding to Inform Technical and Commercial Support Needed As Well As Near-Term Production Output Forecast	23-01-24	AQ
Recipharm invests in its single dose nasal platform capabilities	22-12-01	AQ
Recipharm bolsters blow-fill-seal capabilities with Lab+	22-10-26	AQ
Recipharm strengthens pre-filled syringe and cartridge offering with new investment	22-10-20	AQ
Biologics Fill/ finish Services Market is projected to be over USD 4.2 billion by 2030 \| Roots Analysis	22-10-07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Recipharm AB (publ)

Equities

RECI B

SE0005757267

Press Releases

Filters